Trulieve stock forecast 2025 sector-wide studies indicate Trulieve

Sector-wide studies indicate Trulieve stock forecast 2025 could align with broader MSO performance trends, especially if national legalization discourse adds momentum to share prices. Despite a $2.1 billion non-cash impairment charge related to previous acquisitions and shifting U.S. cannabis legalization forecasts, adjusted net income increased 45% to $9 million. The company also paid down roughly $100 million in debt while retaining a good liquidity position of $256 million in cash and securities. Cresco Labs is a vertically integrated multi-state cannabis operator in the US. A leading US cannabis company, it is known for its strong brands like Cresco, High Supply and Good News. Investor sentiment around Trulieve stock forecast 2025 is partly driven by the expectation of improved free cash flow levels, projected at $30–$35 million for the fiscal year.